Portal Login:
  • Clients
  • Providers
  • Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer
    Portal Login:
  • Clients
  • Providers
  • About Mitchell MCN
  • Careers
  • MCNTalk
  • Contact Us

Mitchell MCN

The Power of a Second Look

  • Services
    • Independent Medical Examinations
    • Medical Peer Reviews
    • Bill Review Services
    • Utilization Reviews
  • Expertise
    • Short and Long-Term Disability
    • Workers’ Compensation
    • Auto/PIP/Casualty/Liability
    • Independent Review Organization Services
  • For Clients
  • For Providers
  • Your Exam
    • About Your Exam
    • About Your External Review
    • Contact & Scheduling
  • Schedule Now
  • About Mitchell MCN
  • MCNTalk
  • Careers
  • Contact Us

MCNTalk
News, Insights & Opinions

Home / MCNTalk / New Gene Tests and the Potential Effect on Long-Term Care In...

May 25, 2017

New Gene Tests and the Potential Effect on Long-Term Care Insurance

Last month the Food and Drug Administration gave its approval for the gene testing company 23andMe to offer tests assessing risks for developing conditions such as Parkinson’s and celiac disease. Other genetics companies are planning to follow suit shortly and offer tests that will give people a better idea of what their “medical futures” look like. Although this may seem like an excellent step forward, these tests could actually prove to be a disaster for companies selling long-term care insurance.  The issue does not currently lie with employment or health insurance because the Genetic Information Nondiscrimination Act protects employees from being asked to take gene tests and results cannot be used in employment decisions. However, unlike medical insurers, companies selling long-term care insurance can ask about health status and are permitted to consider future health when making decisions on whom they will insure and how much they will charge. The issue for these companies is that they believe many customers will choose not to reveal this information and genetics companies promise not to disclose anything to third parties.

Increasing numbers of people at low risk might decide the insurance was not worth the rising price. Even many at high risk would eventually find the policies unaffordable. It is the definition of an insurance death spiral. – New York Times

Read more from the New York Times here.

Share this:

  • Twitter
  • Email
  • More
  • Facebook
  • Reddit
  • Print

1 Comment

Previous Post
Next Post

Reader Interactions

Comments

  1. Morgan Colin says

    June 5, 2017 at 7:24 am

    Great article and very well explained. I believe in professionals so this is a very useful article for everyone. Many thanks for your share.

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

three × four =

Primary Sidebar

Recent Posts

  • March Clinic Calendars Are Available
  • Mitchell MCN’s Client Portal Login Page is Changing
  • IRO Team to Host Webinar about Genetics on Dec. 5, 2019
  • December Clinic Calendars are Now Available
  • Mitchell MCN’s IRO Team to Host CEU in December

Archives

Footer


  • Twitter
  • LinkedIn

Quick Links

  • Services
  • Expertise
  • About Mitchell MCN
  • Careers

Division Headquarters

Mitchell MCN
1301 5th Ave., Ste. 2900
Seattle, WA 98101

See all offices

Email Us

General Inquiries: info@mcn.com
Sales & Marketing: marketing@mcn.com

Call Us

206.343.6100
800.248.6269

© Copyright 2021 Mitchell International, Inc. All Rights Reserved.

  • Privacy Policy
  • Sitemap
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.